Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon-α Combined With ATO and Venetoclax for Arsenic-resistant APL
NCT06450145Recruiting
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- May 2024
- Primary completion
- Dec 2025
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Open-label, single-arm trial of interferon alfa-2b in acute promyelocytic leukemia (APL), sponsored by Zhejiang Provincial People's Hospital. Primary endpoint: Objective Response Rate at 6 weeks. Started May 2024; status: recruiting.
02
Drugs
interferon alfa-2b
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT06450145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06450145.